Skip to main content
Log in

Elevated HR in HFrEF linked to worse outcomes, higher cost

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. The analysis was supported by a research agreement between Amgen Inc. and Duke University.

Reference

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elevated HR in HFrEF linked to worse outcomes, higher cost. PharmacoEcon Outcomes News 746, 20 (2016). https://doi.org/10.1007/s40274-016-2798-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-2798-6

Navigation